London headquartered Enso Group to transform diagnostic infrastructure in 43 hospitals in India.
Noida, UP -- (SBWIRE) -- 01/30/2014 -- Recognizing the need for increased quality in healthcare and the inadequacy of infrastructure to provide the same, the government is resorting to Public Private Partnership to enhance the status of healthcare services in India. The London headquartered US$ 7 Billion Enso Group, along with Wipro GE Healthcare, has tied up with the state governments of Maharashtra and Punjab to upgrade diagnostic facilities in 43 civil hospitals, 22 in Maharashtra and 21 in Punjab.
According to our report, “Indian Diagnostic Market Outlook to 2017”, these new ventures will continue to create a need for diagnostic products, resulting in an INR 134 Billion market by 2017. The report provides an insight into the various trends that will shape the market in the coming years. It elaborates on the role of Private Public Partnerships, E Health points and rising automation. The report divides the diagnostic equipment market into various segments such as Biochemistry, Hematology, Immunochemistry, and Coagulation etc, which are then studied in terms of the major tests and mechanism, market outlook and the key players operating in the segment.
The report also discusses the regulatory environment in India with respect to diagnostic products. At the end, the competitive scenario has been analyzed in terms of the manufacturers and service providers, where a strength and weakness analysis has been performed to compare the players. It also talks about the recent activities of key players to depict an objective picture of the industry to clients to help them make sound investment decisions.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM645.htm
Some of our Related Reports are:
- China Diabetes Market Outlook 2018 (http://www.rncos.com/Report/IM648.htm)
- Emerging NIPT Market in Asia Pacific (http://www.rncos.com/Report/IM646.htm)
- Indian Diagnostic Services Market Outlook 2017 (http://www.rncos.com/Report/IM644.htm)
- US Proton Therapy Outlook 2017 (http://www.rncos.com/Report/IM631.htm)
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
ABOUT RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.